Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 782

1.

Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin.

Loustaud-Ratti V, Maynard M, Thevenon S, Pradat P, Rousseau A, Alain S, Deny P, Gagnieu MC, Tran A, Dao T, Silvain C, Lunel-Fabiani F, Picard N, Zublena I, Marquet P, Trepo C; RIBAJUSTE Group.

Ther Drug Monit. 2016 Dec;38(6):684-692.

PMID:
27559840
2.

Comparative effectiveness of immediate antiretroviral therapy versus CD4-based initiation in HIV-positive individuals in high-income countries: observational cohort study.

Lodi S, Phillips A, Logan R, Olson A, Costagliola D, Abgrall S, van Sighem A, Reiss P, Miró JM, Ferrer E, Justice A, Gandhi N, Bucher HC, Furrer H, Moreno S, Monge S, Touloumi G, Pantazis N, Sterne J, Young JG, Meyer L, Seng R, Dabis F, Vandehende MA, Pérez-Hoyos S, Jarrín I, Jose S, Sabin C, Hernán MA; HIV-CAUSAL Collaboration.

Lancet HIV. 2015 Aug;2(8):e335-43. doi: 10.1016/S2352-3018(15)00108-3. Epub 2015 Jul 7.

3.

Hepatitis: After HCV cure, HBV cure?

Lucifora J, Trepo C.

Nat Rev Gastroenterol Hepatol. 2015 Jul;12(7):376-8. doi: 10.1038/nrgastro.2015.103. Epub 2015 Jun 23.

PMID:
26100368
4.

Cryptococcosis Serotypes Impact Outcome and Provide Evidence of Cryptococcus neoformans Speciation.

Desnos-Ollivier M, Patel S, Raoux-Barbot D, Heitman J, Dromer F; French Cryptococcosis Study Group.

MBio. 2015 Jun 9;6(3):e00311. doi: 10.1128/mBio.00311-15.

5.

Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases.

Petit MA, Berthillon P, Pradat P, Arnaud C, Bordes I, Virlogeux V, Maynard M, Bailly F, Zoulim F, Chemin I, Trépo C.

Clin Res Hepatol Gastroenterol. 2015 Dec;39(6):699-704. doi: 10.1016/j.clinre.2015.03.002. Epub 2015 Apr 18.

PMID:
25900002
6.

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F.

Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10. Review.

PMID:
25670809
7.

Boosted lopinavir- versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: a prospective study of HIV-infected individuals in high-income countries.

HIV-CAUSAL Collaboration, Cain LE, Phillips A, Olson A, Sabin C, Jose S, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, Reiss P, Young J, Fehr J, Touloumi G, Paparizos V, Esteve A, Casabona J, Monge S, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Dabis F, Vandenhende MA, Abgrall S, Costagliola D, Hernán MA.

Clin Infect Dis. 2015 Apr 15;60(8):1262-8. doi: 10.1093/cid/ciu1167. Epub 2015 Jan 6.

8.

HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers.

Kay A, Melo da Silva E, Pedreira H, Negreiros S, Lobato C, Braga W, Muwonge R, Dény P, Reis M, Zoulim F, Trepo C, D'Oliveira A Jr, Salcedo JM, Schinoni MI, Parana R.

J Viral Hepat. 2014 Dec;21(12):921-4. doi: 10.1111/jvh.12267. Epub 2014 Jul 9.

PMID:
25040045
9.

Hepatitis B virus infection.

Trépo C, Chan HL, Lok A.

Lancet. 2014 Dec 6;384(9959):2053-63. doi: 10.1016/S0140-6736(14)60220-8. Epub 2014 Jun 18. Review.

PMID:
24954675
10.

Health-related quality of life of people living with HIV followed up in hospitals in France: comparing trends and correlates between 2003 and 2011 (ANRS-VESPA and VESPA2 national surveys).

Douab T, Marcellin F, Vilotitch A, Protopopescu C, Préau M, Suzan-Monti M, Sagaon-Teyssier L, Lert F, Carrieri MP, Dray-Spira R, Spire B; ANRS-VESPA2 Study Group.

AIDS Care. 2014;26 Suppl 1:S29-40. doi: 10.1080/09540121.2014.906553. Epub 2014 Apr 14.

PMID:
24731158
11.

Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma.

Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I, Benjelloun S.

Liver Int. 2014 Jul;34(6):e144-50. doi: 10.1111/liv.12482. Epub 2014 Mar 11.

PMID:
24502524
12.

Diversity of hepatocellular carcinoma clones bearing hematopoietic malignancies-related chromosomal translocation.

Parent R, Plissonnier ML, Bancel B, Liao WL, Rumin S, Asaad R, Till M, Sanlaville D, Zoulim F, Trépo C, Marion MJ.

J Cell Biochem. 2014 Apr;115(4):666-77. doi: 10.1002/jcb.24706.

PMID:
24453043
13.

A brief history of hepatitis milestones.

Trepo C.

Liver Int. 2014 Feb;34 Suppl 1:29-37. doi: 10.1111/liv.12409. Review.

PMID:
24373076
14.

Predictors of the therapeutic response in hepatitis C. A 2013 update.

Arnaud C, Trépo C, Petit MA.

Clin Res Hepatol Gastroenterol. 2014 Feb;38(1):12-7. doi: 10.1016/j.clinre.2013.08.003. Epub 2013 Nov 21. Review.

PMID:
24268305
15.

Improved fibrosis staging by elastometry and blood test in chronic hepatitis C.

Calès P, Boursier J, Ducancelle A, Oberti F, Hubert I, Hunault G, de Lédinghen V, Zarski JP, Salmon D, Lunel F; ANRS HC EP 23 Fibrostar Study.

Liver Int. 2014 Jul;34(6):907-17. doi: 10.1111/liv.12327. Epub 2013 Oct 16.

PMID:
24102852
16.

Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.

Arnaud C, Pradat P, Spaziante M, Berthillon P, Maynard M, Taliani G, Chemin I, Trépo C, Petit MA.

Antivir Ther. 2013;18(8):1027-32. doi: 10.3851/IMP2671. Epub 2013 Aug 15.

PMID:
23948510
17.

Is clinical practice concordant with the changes in guidelines for antiretroviral therapy initiation during primary and chronic HIV-1 infection? The ANRS PRIMO and COPANA cohorts.

Krastinova E, Seng R, Yeni P, Viard JP, Vittecoq D, Lascoux-Combe C, Fourn E, Pahlavan G, Delfraissy JF, Goujard C, Meyer L; ANRS PRIMO and COPANA Cohorts.

PLoS One. 2013 Aug 1;8(8):e71473. doi: 10.1371/journal.pone.0071473. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/aed12a66-9c76-4e49-806b-881a2fe23bba. Goujard, Cecile [added].

18.

AST/ALT ratio is not an index of liver fibrosis in chronic hepatitis C when aminotransferase activities are determinate according to the international recommendations.

Guéchot J, Boisson RC, Zarski JP, Sturm N, Calès P, Lasnier E; ANRS HCEP 23 Fibrostar Group.

Clin Res Hepatol Gastroenterol. 2013 Nov;37(5):467-72. doi: 10.1016/j.clinre.2013.07.003. Epub 2013 Aug 8.

PMID:
23932706
19.

Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA).

Martel N, Gomes SA, Chemin I, Trépo C, Kay A.

J Virol Methods. 2013 Nov;193(2):653-9. doi: 10.1016/j.jviromet.2013.07.045. Epub 2013 Aug 5.

PMID:
23928222
20.

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group.

Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. doi: 10.1128/AAC.00565-13. Epub 2013 Jul 15.

Supplemental Content

Loading ...
Support Center